Key result
Cirrhotic cardiomyopathy was associated with an increased risk for posttransplant cardiovascular disease in liver transplant recipients (HR 2.57; 95% CI 1.2-5.5; P=0.016).
Why the study?
Diagnostic criteria for cirrhotic cardiomyopathy (CCM) were recently revised, but the prevalence of CCM by these new criteria and its impact on posttransplant cardiovascular disease remained to be evaluated.
Does cirrhotic cardiomyopathy predict posttransplant cardiovascular disease in liver transplantation recipients?
Population
141 liver transplantation recipients with decompensated cirrhosis
Comparison
CCM defined by 2020 criteria vs no CCM
Design
Single-center retrospective matched cohort study with blinded echocardiographic analysis
Authors
Loading...
New CCM criteria identify higher post-LT CVD risk in observational data; leaves open whether screening changes management or outcomes.
Cohort (n=141)
Single-blind
No
Does cirrhotic cardiomyopathy predict posttransplant cardiovascular disease in liver transplantation recipients?
Hazard Ratio: 2.57 (95% CI 1.2–5.5)
p-value: p=0.016
Cirrhotic cardiomyopathy, defined by the 2020 diagnostic criteria, affects approximately one-third of decompensated liver transplant candidates and significantly predicts an increased risk for new cardiovascular disease following transplantation.
Izzy et al. (2021) conducted a cohort in Decompensated cirrhosis undergoing liver transplantation (n=141). Cirrhotic cardiomyopathy (CCM) vs. No cirrhotic cardiomyopathy was evaluated on Posttransplant cardiovascular disease (new coronary artery disease, congestive heart failure, atrial and ventricular arrhythmia, and stroke) (HR 2.57, 95% CI 1.2-5.5, p=0.016). Cirrhotic cardiomyopathy was associated with an increased risk for posttransplant cardiovascular disease in liver transplant recipients (HR 2.57; 95% CI 1.2-5.5; P=0.016).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: